James E. Galvin, MD, MPH

James E. GalvinDr. Galvin is Professor of Neurology, Psychiatry and Population Health.  He received his Bachelor of Arts degree in Chemistry from New York University in 1986, Masters of Science in Nutrition from Rutgers University in 1988, M.D. from the University of Medicine and Dentistry of New Jersey in 1992 and Masters of Public Health from St. Louis University in 2004. After completing his residency in neurology, he completed post-doctoral training at the Center for Neurodegenerative Disease Research in the Department of Pathology and Laboratory Medicine under the direction of John Q. Trojanowski M.D., Ph.D and Virginia M-Y Lee, Ph.D.  In March of 2010, he joined the faculty of New York University Langone School of Medicine as Professor of Neurology and Psychiatry, where he serves as Director of Clinical Operations for Brain Aging, Director of the Pearl S. Barlow Memory Evaluation and Treatment Center and Education Core Leader and Associate Director of the NIH-funded Alzheimer’s Disease Center. Dr. Galvin has published over 85 scientific papers covering basic, clinical and translational science in the area of neurodegenerative disorders, dementia and cognitive aging, is the editor of two textbooks on dementia and leads numerous clinical trials investigating new therapeutics for Alzheimer’s disease and related disorders.

Research Interests

  • Community Detection of Dementia:  Dr. Galvin has led efforts to develop a number of dementia screening tools, including the AD8, a brief informant interview to translate research findings to community settings.  He has a new R01 to do cross-cultural validation of dementia screening methods in comparison with Gold Standard clinical evaluations and biomarker assays.
  • Modeling of cognitive change in older adults:  His team has developed sophisticated statistical models to explore transition points in clinical, cognitive, functional, behavioral and biological markers of disease in health aging, mild cognitive impairment, Alzheimer Disease, and Parkinson’s disease.
  • Biomarkers of Lewy Body Disorders: Lewy Body disease (LBD) affects over 1.3 million Americans but is poorly recognized and diagnosis is often significantly delayed.  Dr. Galvin has been working to improve clinical detections by combining biomarkers including high density EEG, functional and structural MRI, PET scans and CSF biomarkers to characterize and differentiate LBD from healthy aging and other neurodegenerative diseases.

Email: James.Galvin@nyumc.org

Representative Publications

  1. Galvin JE, Price JL, Yan L, Morris JC, Sheline YI. Patterns of resting BOLD functional MRI activation differentiate Dementia with Lewy Bodies from Alzheimer Disease. Neurology 76:1797-1803,2011. (PMCID: 3100121)
  2. Carpenter CR, Bassett E, Fischer G, Shirskekan J, Galvin JE, Morris JC.  Four sensitive screening tolos to detect cognitive impairment in Geriatric Emergency department patients: Brief Alzheimer’s screen, Short Blessed Test, Ottawa3DY, and the Caregiver administered AD8. Acad Emerg Med, 18:374-384, 2011 (PMCID: 3080244)
  3. Biagioni MC, Galvin JE. Using Biomarkers to Improve Detection of Alzheimer’s Disease. Neurodegen Dis Management 1: 127-140, 2011. (NIHMSID: 303397)
  4. Yang YH, Galvin JE, Morris JC, Lai CL, Chou MC, Lie CK.  Application of AD8 questionnaire to screen very mild dementia in Taiwanese.  Am J Alz Dis Other Dem, 26:134-138, 2011.
  5. Galvin JE, Meuser TM, Morris JC. Improving physician awareness of Alzheimer’s disease and enhancing recruitment: The Clinician Partner Program. Alz Dis Assoc Disord 2011 Mar 10. [Epub ahead of print] (PMC Journal – In Process)
  6. Galvin JE. Dementia Screening, Biomarkers and Protein Misfolding: Implications for Public Health and Diagnosis. Prion, 5:16-21;2011. (PMCID: 3038001)
  7. Leggett AN, Zarit SH, Taylor A, Galvin JE. Stress and burden among caregivers of patients with Lewy Body Dementia.  The Gerontologist 51:76-85, 2011.
  8. Johnson DK, Galvin JE. Longitudinal changes in cognition in Parkinson disease with and without dementia. Dement Geriatr Cog Disord, 31:98-108, 2011 (PMCID: 3047760)
  9. Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE. The neurotoxicity of DOPAL: Behavioral and stereological evidence for a role for DOPAL in Parkinson disease pathogenesis, PLoS One, 2010 Dec 13;5(12):e15251 (PMCID:3001493)
  10. Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC.  Relationship of dementia screening tests with biomarkers of Alzheimer’s Disease. Brain, 133:3290-300,2010.  (PMCID: 2965421).
  11. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen P. Docosahexanoic acid supplementation and cognitive decline in Alzheimer’s disease. J Am Med Assoc, 304:1903-1911,2010
  12. Galvin JE, Kuntemeier B, Al-Hammadi N, Germino J, Murphy-White M, McGillick J.  “Dementia-Friendly Hospitals: Care not crisis” Improving the care of the hospitalized patient with dementia. Alz Dis Assoc Disord, 24:372-379,2010. (PMCID: 2955811)
  13. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: The caregiver experience of clinical care. Parkinson Rel Disord, 16:388-392, 2010. (PMCID: 2916037)
  14. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: Caregiver burden and unmet needs. Alz Dis Assoc Disord, 24:177-181, 2010. (PMCID: 2879080)
  15. Escandon A, Al-Hammadi N, Galvin JE. Impact of cognitive fluctuations on neuropsychological performance in aging and dementia. Neurology, 74:210-217; 2010. (PMCID: 2809035)
  16. Wang L, Harms MP, Stags J, Xiong C, Morris JC, Csernansky JG, Galvin JE. Treatment with Donepezil Does Not Alter Longitudinal Hippocampal Surface Changes In Mild Alzheimer Disease. Arch Neurol, 67:99-106 2010. (PMCID: 2855123)